As the markets are recovering steadily, small cap stocks are back in focus and seem to have outclassed the A-listers. Some of them have generated over 1,500 per cent returns in the past 52-week period, better than most of the global indices.
However, investing in these stocks could be risky as these stocks are highly volatile and can be influenced by institutional investors. Therefore, one might seek help from professionals before taking a call on these stocks.
UK-based drug maker Synairgen (LON: SNG) has underpinned its growth on the positive interim results of SNG001 (Covid-19 treatment) and is seeking regulatory approvals. Rising mutations of Covid-19 could make vaccines less effective.
